Notice: Prospective Granting of a Co-Exclusive License

Federal Register: October 3, 2008 (Volume 73, Number 193)              
                  Page 57630

AGENCY: Technology Transfer Office, Centers for Disease Control and 
Prevention (CDC), Department of Health and Human Services (HHS).

ACTION: Notice.

SUMMARY: This is a notice in accordance with 35 U.S.C. 209(e) and 37 
CFR 404.7(a)(1)(i) that the Technology Transfer Office, Centers for 
Disease Control and Prevention (CDC), Department of Health and Human 
Services (DHHS), is contemplating the granting of a co-exclusive 
worldwide license to practice the invention embodied in the patent 
application referred below to Mk-IX Technologies, having a place of 
business in Huntsville, Alabama. CDC intends to grant rights to 
practice this invention to no more than one other co-licensee. The 
patent rights in these inventions have been assigned to the government 
of the United States of America. The patent application to be licensed 
is:

Non-Provisional Patent Application

    Title: Wipes and Methods for Removal of Metal Contamination from 
Surfaces.
    Serial No. 11/039,178.
    Filing date: 01/18/2005.
    Issue Date: Patent pending.
    The prospective exclusive license will be royalty-bearing and will 
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7.

ADDRESSES: Requests for a copy of these patent applications, inquiries, 
comments, and other materials relating to the contemplated license 
should be directed to Andrew Watkins, Director, Technology Transfer 
Office, Centers for Disease Control and Prevention (CDC), 4770 Buford 
Highway, Mailstop K-79, Atlanta, GA 30341, telephone: (770) 488-8610; 
facsimile: (770) 488-8615. Applications for an exclusive license filed 
in response to this notice will be treated as objections to the grant 
of the contemplated co-exclusive license. Only written comments and/or 
applications for a license which are received by CDC within thirty days 
of this notice will be considered. Comments and objections submitted in 
response to this notice will not be made available for public 
inspection, and, to the extent permitted by law, will not be released 
under the Freedom of Information Act, 5 U.S.C. 552. A signed 
Confidential Disclosure Agreement will be required to receive a copy of 
any pending patent application.

    Dated: September 26, 2008.
James D. Seligman,
Chief Information Officer, Centers for Disease Control and Prevention.
 [FR Doc. E8-23398 Filed 10-2-08; 8:45 am]

BILLING CODE 4163-18-P